Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer [1] (multiple letters)

New England Journal of Medicine

Volumn 345, Issue 2, 2001, Pages 144-146

  Sargent, Daniel J ^a   Niedzwiecki, Donna ^b   O'Connell, Michael J ^a   Schilsky, Richard L ^c   Ledermann, Jonathan A ^d   Leonard, Pauline ^d   Seymour, Matthew ^e   Miller, Langdon L ^f  

^a MAYO CLINIC   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Cancer and Leukemia Group B Central Office   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e United Kingdom   (United Kingdom)

^f Pharmacia   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INFUSION; LETTER; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035849938     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200107123450213     Document Type: Letter

References (0)